Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

Inclusion criteria

• Subjects of childbearing potential must agree to use hormonal or two forms of nonhormonal contraception (dual contraception) consistently during the screening, treatment, and follow-up periods of the study.
• Have one of the following clinical diagnoses for at least 3 months before screening: Schizophrenia, Schizoaffective Disorder, or Mood Disorder
• Have a clinical diagnosis of neuroleptic-induced TD for at least 3 months before screening.
• Be on stable doses if using maintenance medication(s) for schizophrenia or schizoaffective disorder, or mood disorder. Subjects with bipolar disorder must be on stable doses of a mood stabilizer.
• Be in general good health.
• Have adequate hearing, vision, and language skills to perform the procedures specified in the protocol.

Exclusion criteria

• Have an active, clinically significant unstable medical condition within 1 month before screening.
• Have a known history of substance (drug) dependence, or substance or alcohol abuse.
• Have a significant risk of suicidal or violent behavior.
• Have been hospitalized for psychiatric disorder within 6 months before Day 1.
• Have a known history of neuroleptic malignant syndrome.
• Have a known history of long QT syndrome or cardiac arrhythmia.
• Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed).
• Are currently taking tetrabenazine or deutetrabenazine, or have used valbenazine (INGREZA) within 30 days of screening.
• Have received an investigational drug within 30 days before Day 1 or plan to use an investigational drug (other than NBI-98854) during the study.
• Have a blood loss ≥550 mL or donated blood within 30 days prior to Baseline.
• Have an allergy, hypersensitivity, or intolerance to VMAT2 inhibitors (eg, tetrabenazine, deutetrabenazine).
• Are currently pregnant or breastfeeding.
• Have HIV or hepatitis B.